CIAM
CLDX icon

Caitong International Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Caitong International Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.1K Sell
1,455
-1,170
-45% -$37.8K 0.01% 695
2026
Q1 		$83.3K Buy
2,625
+2,603
+11,832% +$71K 0.02% 632
2025
Q4 		$598 Buy
+22
New +$579 ﹤0.01% 1445
2025
Q3 		– Sell
-78
Closed -$1.59K – 2025
2025
Q2 		$1.59K Buy
78
+46
+144% +$895 ﹤0.01% 1450
2025
Q1 		$581 Buy
+32
New +$715 ﹤0.01% 1729

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caitong International Asset Management's CLDX Position: Q2 2026 in Review

Caitong International Asset Management reduced its Celldex Therapeutics (CLDX) stake by 45% in Q2 2026, selling an estimated $37.8K and leaving 1,455 shares worth $54.1K. The position accounts for 0.01% of the portfolio, ranked #695.

Caitong International Asset Management first reported a position in CLDX in Q1 2025 and has held it in 5 quarters since. The position peaked at $83.3K in Q1 2026. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Caitong International Asset Management held 1,455 shares of Celldex Therapeutics worth $54.1K as of Q2 2026.
  • Caitong International Asset Management sold 1,170 Celldex Therapeutics shares in Q2 2026, an estimated $37.8K.
  • Celldex Therapeutics made up 0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #695 holding.
  • Caitong International Asset Management first reported a position in Celldex Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Caitong International Asset Management's Celldex Therapeutics position peaked at $83.3K in Q1 2026.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.